Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.
- First GI flexible imaging prototype completed
- Pre-clinical study launched at University Medical Center Mainz
- Assessment of Gen2 real-time imaging for GI disease diagnosis
- Data to support AI algorithm development with Monash University
- Plans underway for clinical trials and Gen3 device development
Optiscan’s Breakthrough in GI Imaging
Optiscan Imaging Ltd (ASX:OIL) has taken a significant step forward in gastrointestinal (GI) diagnostics with the completion of its first flexible prototype designed to capture high-resolution images from the GI tract. This milestone coincides with the commencement of a pre-clinical study at the University Medical Center Mainz in Germany, led by renowned gastroenterologist Professor Ralph Kiesslich.
The study aims to evaluate the real-time imaging capabilities of Optiscan’s Gen2 technology on GI tissues, focusing on diseases such as colorectal cancer, a leading global cause of cancer mortality. By enabling live, cellular-level visualization, Optiscan hopes to improve early detection and precision treatment, addressing the limitations of traditional invasive and time-consuming diagnostic methods.
Strategic Collaboration and Technology Development
Dr Camile Farah, Optiscan’s CEO and Managing Director, personally activated the study in Germany, underscoring the company’s commitment to advancing GI diagnostics. The collaboration with Professor Kiesslich, who played a key role in Optiscan’s earlier Gen1 device development, is expected to accelerate the refinement of the Gen3 flexible endomicroscope, slated for future clinical trials.
Beyond imaging, the study will generate valuable datasets to fuel AI algorithm development in partnership with Monash University’s Cooperative Research Centre for Cancer (CRC-P). This integration of AI aims to enhance diagnostic accuracy and streamline clinical decision-making, potentially transforming GI disease management.
Addressing a Global Health Challenge
GI diseases, particularly colorectal cancer, represent a significant global health burden, with nearly 2 million new cases and over 930,000 deaths worldwide reported in 2020. Current diagnostic approaches often rely on invasive biopsies and delayed histopathology results, which can hinder timely intervention.
Optiscan’s technology offers a paradigm shift by providing real-time, high-resolution imaging at the cellular level during endoscopic procedures. This capability could reduce the need for multiple biopsies, enable immediate identification of abnormalities, and improve patient outcomes through faster, more precise interventions.
Looking Ahead
With ethical clearance for the clinical phase pending, Optiscan is positioning itself to re-enter the GI endoscopy market with a private label device, leveraging its advanced imaging technology. The staged approach, from pre-clinical studies to clinical trials and AI integration, reflects a thoughtful development strategy aimed at delivering impactful healthcare solutions.
As the company progresses, the medical community and investors alike will be watching closely to see how Optiscan’s innovations translate into clinical practice and market success.
Bottom Line?
Optiscan’s GI imaging study marks a crucial step toward transforming diagnosis and treatment of gastrointestinal diseases worldwide.
Questions in the middle?
- How will the Gen2 prototype’s imaging performance compare to existing GI diagnostic tools in clinical settings?
- What timeline does Optiscan anticipate for regulatory approvals and commencement of clinical trials?
- How effectively will AI algorithms developed from this study improve diagnostic accuracy and workflow?